CDC has updated its HHS Vaccination Operational Planning Guide to help jurisdictions and providers plan for a potential transition in guidance for COVID-19 vaccines. The guide addresses the impact of potentially having the bivalent mRNA COVID-19 vaccines authorized (by FDA) and recommended (by CDC) as primary doses in the COVID-19 vaccination series. Per the guide (page 1):
If authorized by FDA, CDC anticipates that a recommendation for bivalent mRNA COVID-19 vaccine to be used for vaccination for all age groups could be implemented as early as week of April 17th [emphasis added]. It is also expected that Novavax and Johnson & Johnson/Janssen monovalent non-mRNA vaccines will continue to be authorized.
We will continue sharing timely updates about COVID-19 vaccination recommendations.
At this time, monovalent mRNA vaccines are no longer available to order.